Intravitreal Injection Endophthalmitis Results: Two Different Rooms

Abstract

Purpose: To compare postoperative complication rates of  intravitreal injections (IVIs) when performed in dedicated rooms versus performed in standard surgical rooms.

Material and methods: Group 1 underwent IVIs in the operating room, Group 2 underwent IVIs in a dedicated room with high-efficiency particulate air filtering device (PFD) on mode (0.02 %). Postoperative complications, room particle counts were evaluated.

Results: A total of 13354 injections consisting of 652 females (48 %) and 680 males (52 %) who had undergone intravitreal injection were reviewed. Endophthalmitis was observed in a total of 3 injections (0,022%), 2 patients in the operating room (0.02%), and 1 patient in the dedicated room.

Conclusion: We found no difference between performing IVIs in a theatre versus in a dedicated room. 

Keywords

• hospital productivity,endophthalmitis,dedicated room,intravitreal injections

References

1. 1- Jager RD, Aiello LP, Patel SC,et al. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24:676698.
2. 2- Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008;145:879-882.
3. 3- Abell RG, Kerr NM, Allen P, et al. Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol. 2012;96:14741478.
4. 4- Van der Reis MI, La Heij EC, De Jong-Hesse Y, et al. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011;31:1449–1469.
5. 5- Elman MJ, Ayala A, Bressler NM, et al. Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122:375-381.
6. 6- Sun Y, Qu Y. Comparison of intravitreal bevacizumab with intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to retinal vein occlusion: a Meta-analysis. Int J Ophthalmol. 2015;8(6):1234-1239.
7. 7- Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014 ;121:2473-2481.
8. 8- Arevalo JF, Jap A, Chee SP, et al. Endogenous endophthalmitis in the developing world. Int Ophthalmol Clin. 2010;50:173-187. 9- Dharan S, Pittet D. Environmental controls in operating theatres. J Hosp Infect. 2002;51:79-84.

9. 10- Lapid-Gortzak R, Traversari R, van der Linden JW, et al. Mobile ultra-clean unidirectional airflow screen reduces air contamination in a simulated setting for intravitreal injection. Int Ophthalmol. 2017; 37(1):131-137.
10. 11- The Royal College of Ophthalmologists, United Kingdom. The UK Guidelines for Intravitreal Injections Procedure 2009.
11. 12- Bande MF, Mansilla R, Pata MP, et al. Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: A systematic review and meta-analysis. Sci Rep. 2017;7:18088.
12. 13- Tabandeh H, Boscia F, Sborgia A, et al. Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting. Retina. 2014; ;34:1823.
13. 14- McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31:654–661.
14. 15- Bhavsar AR, Stockdale CR, Ferris FL III, et al. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical anti biotics Arch Ophthalmol 2012;130:809–810.
15. 16- Cheung CS, Wong AW, Lui A, et al. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 2012;119:1609– 1614.
16. 17- International Organization for Standardization, ISO 14644-1 (2013) Cleanrooms and associated controlled environments—Part 1: Classification of air cleanliness.
17. 18- Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014; 34 Suppl 12: S1-S18.
18. 19- Schimel AM, Scott IU, Flynn HW Jr. Endophthalmitis after intravitreal injections: should the use of face masks be the standard of care? Arch Ophthalmol. 2011;129:1607-1609.
19. 20- Fineman MS, Hsu J, Spirn MJ, et al. Bimanual assisted eyelid retraction technique for intravitreal injections. Retina. 2013;33:1968-1970.
20. 21- Brynskov T, Kemp H, Sørensen TL. No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting. Retina. 2014;34(5):951-957.
21. 22- Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17: 857–872.
22. 23- Freiberg FJ, Brynskov T, Munk MR, et al. Low endophthalmitis rates after intravitreal anti-vascular endothelial growth factor injections in an operation room: A retrospective Multicenter Study. Retina 2017; 37(12): 23412346.